Dr. Anthony Maida, PhD
Chief Executive Officer
Dr. Maida is a scientific icon in the clinical development of immunotherapies to treat patients with cancer. He has served in several executive roles, including, Chairman, CEO, COO, CSO, CFO, and business development. Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc., focused on cancer immunotherapy and infectious disease programs. He is a member of the American Society of Clinical Oncology (“ASCO”), the American Association for Cancer Research (“AACR”), the Society of Neuro-Oncology (“SNO”), the International Society for Biological Therapy of Cancer (“iSBTc”) and the American Chemical Society (“ACS”).
Kit S. Lam, MD, PhD
Chair of Scientific Advisory Board
Dr. Lam is recognized as one of the pioneers who started the field of synthetic combinatorial chemistry. In the last 15 years, Dr. Lam has expanded his research program into nanomedicine. In 2022, Dr. Lam published data on the novel nano immuno-engager (“NIE”) platform that transforms into nanofibriles at the tumor sites, resulting in the conversion of an immunological “cold tumor” to “hot tumor,” with this research creating the scientific foundation for the formation of T-NanoBio Therapeutics, Inc. Dr Lam has been serving in the last 20 years as the co-director of the Cancer Therapeutic Program of UC Davis NCI-designated Comprehensive Cancer Center.
Tim Obara
Chief Business Officer
Tim Obara is a senior executive with more than 30 years of pharmaceutical sector and academia experience in product commercialization, corporate strategy, business development and CMC roles. Most recently, Tim was Vice President of Business Development at Genenta Science SpA, and prior to that he led the gene therapy program for comparative medicine at the University of Pennsylvania. Previously, he was Vice President at Amicus responsible for the operation and build-out of the gene therapy CMC organization. He brings global commercial experience across a broad range of therapeutic area.
William Ashton
William L. Ashton is a former Fortune 100 senior executive with over 30 years’ experience in the biotechnology and pharmaceutical business. Mr. Ashton retired from a lengthy career at Amgen Inc., the world's largest biotechnology firm. Following his retirement from Amgen, Mr. Ashton joined the University of Sciences in Philadelphia (formerly the Philadelphia College of Pharmacy and Science). There he served in various roles including the Dean of the Mayes College of Healthcare Business and Policy, and as Assistant Professor of Healthcare Business. Later he served as the Senior Vice President of External Affairs reporting to the President of the University. Since the beginning of 2013, Mr. Ashton has been a principal at Harrison Consulting Group, LLC, a privately held biopharmaceutical consulting firm with expertise in commercialization, payer strategy, and reimbursement.
Richard B. Slansky
Richard Slansky is a senior financial executive with more than 30 years of experience as Chief Financial Officer in various biopharmaceutical diagnostic and life science companies, including Genenta, Oncosec, Biological Dynamics and Genmark Diagnostics. His experience spans public and private companies, pre-revenue to revenue growth, and commercial healthcare and high technology environments. He has been responsible for strategic vision and oversight of financial and operational teams, organizational leadership and creating maximum stakeholder value. He also serves on the Board of Directors of several private companies, including Nuclear RNA Networks, an early-stage RNA gene transcription therapeutics company.
COMPANY OVERVIEW
T-NanoBio Therapeutics, Inc., a Delaware corporation, is a new emerging biotechnology company developing an innovative therapeutic platform based on transformable peptide nanoparticles. The technology consists of bispecific peptides that self-assemble, targeting tumor cells and cytotoxic T-cells, which result in a potent anti-tumor response in multiple oncology indications. Our nano immuno-engager (“NIE”) platform can harness a patient’s own immune system against cancer, while our HER2+ platform will offer a new treatment paradigm for treating HER2+ tumors. Both platforms offer a new dimension of therapeutic treatment as a potential cure for cancer.
OUR MISSION
To create a patient-focused, science-driven, innovative life science company developing therapeutic products that change the lives of cancer patients for the better, across a broad range of solid tumor indications by addressing and solving the existing challenges in cancer treatment of tolerability, durability and effectiveness.
"We look forward to developing our transformable peptide nanoparticle platform with the goal to ultimately make next-generation immunotherapies for cancers a reality for patients and physicians"
- Dr. Anthony E. Maida III, CEO
OUR TEAM
The Leadership Team is comprised of industry veterans with expertise in all areas of science, clinical studies, finance, business, CMC, commercialization and corporate development with over 120 years of combined experience.
Our internal capabilities are further strengthened by our Board of Directors, bringing business expertise and our Scientific Advisory Board, which consists of world renowned scientists, clinicians, key opinion leaders in the field immuno-oncology and immunology.
Anthony Maida III, PhD
CEO and Chairman of the Board
Learn more
Kit Lam, MD, PhD
Chair of Scientific Advisory Board
Learn more
Anthony Maida III, PhD
CEO and Chairman of the Board
Learn more
Kit Lam, MD, PhD
Chair of Scientific Advisory Board
Learn more
Kit Lam, MD, PhD
Chairman of Scientific Advisory Board
Distinguished Professor, Department of Biochemistry & Molecular Medicine, Hematology & Oncology, Sue Jane Leung Presidential Chair in Cancer Research, UC Davis, Sacramento, CA
David Gandara, MD
Professor at UC Davis NCI designated Comprehensive Cancer Center, Sacramento, CA
Jerome Galon, PhD
Director of Research at INSERM and Head of an INSERM laboratory at the Cordeliers Research Center in Paris, France.
Jose Lutzky, MD
Director, Cutaneous Oncology at Sylvester Comprehensive Cancer Center
Kim Margolin, MD
Medical Director of the Melanoma Program at Saint John’s Cancer Institute (SJCI), Santa Monica, CA
Primo Lara, MD
Director UC Davis NCI designated Comprehensive Cancer Center, Executive Associate Dean, Cancer Programs, Professor, Department of Internal Medicine, Sacramento CA
James Talmadge, PhD
Professor, Department of Pathology and Microbiology, UNMC, Omaha, NE
